About Us
ImmuneMed Inc. utilizes human's own immunity against Infectious Diseases. With the belief that it is the most basic solution, we have been researching for many years.
The Novel Conceptual Drug Development through Innovative Research
Greeting
ImmuneMed Inc. was established with the corporate goal of 'contributing to the healthy life of mankind free from infectious diseases.' We would like to ask our researchers who are working with the ever-day and night virus to open new horizons in medical history around the world.
R & D
We are conducting research with the belief that leveraging human immunity is the most basic solution to various diseases. We are developing and developing VSF (Virus Suppressing Factor), an antiviral source.
R & D
We are conducting research with the belief that leveraging human immunity is the most basic solution to various diseases. We are developing and developing VSF (Virus Suppressing Factor), an antiviral source.
Products
- COVID-19 IgM/IgG Rapid
- Qualitative Test to detect IgM and IgG specific antibodies to SARS-CoV-2 in human serum or plasma.
- Leptospira Rapid
- Qualitative Test to detect antibody IgM and IgG specific to Leptospira existing in human bloods(Serum, Plasma & Whole Blood).
- Leptospira IgM Duo Rapid
- Semi-quantitative Test to detect antibody IgM and IgG specific to Leptospira existing in human bloods(Serum, Plasma & Whole Blood).
- Scrub Typhus Rapid
- Qualitative Test to detect antibody IgM and IgG specific to Orientia tsutsugamushi existing in human bloods(Serum, Plasma & Whole Blood).
News & Press
Press
Release
Release
[Press Release] ImmuneMed's hzVSF-v13, COVID-19 clinical trials accelerate
development of the treatment
2021-01-08
Press
Release
Release
COVID-19 Phase 2 Clinical Study Approval (Italy), December 18th, 2020
2020-12-21
Press
Release
Release
Obtaining Approval Letter of Investigational New Drug (IND) for COVID-19 Phase 2
Study in Republic of Korea on 7th December, 2020
2020-12-07
Press
Release
Release
COVID-19 Phase 2 Clinical Study Approval (Indonesia), December 1st, 2020
2020-12-01